BioMarin Pharmaceutical Inc.
BMRN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $10,400 | $10,523 | $13,499 | $12,534 |
| - Cash | $1,250 | $1,214 | $1,049 | $943 |
| + Debt | $597 | $604 | $602 | $603 |
| Enterprise Value | $9,747 | $9,914 | $13,053 | $12,194 |
| Revenue | $776 | $825 | $745 | $747 |
| % Growth | -6% | 10.8% | -0.3% | – |
| Gross Profit | $636 | $675 | $594 | $611 |
| % Margin | 82% | 81.8% | 79.7% | 81.8% |
| EBITDA | -$5 | $319 | $263 | $195 |
| % Margin | -0.7% | 38.7% | 35.3% | 26.2% |
| Net Income | -$31 | $241 | $186 | $125 |
| % Margin | -4% | 29.1% | 24.9% | 16.7% |
| EPS Diluted | -0.16 | 1.23 | 0.95 | 0.64 |
| % Growth | -113% | 29.5% | 48.4% | – |
| Operating Cash Flow | $369 | $185 | $174 | $186 |
| Capital Expenditures | -$28 | -$17 | -$17 | -$20 |
| Free Cash Flow | $340 | $168 | $158 | $165 |